Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
Ontology highlight
ABSTRACT: Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those resistant or intolerant to prior therapy. In the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE), bosutinib demonstrated a significantly higher major molecular response rate compared with imatinib, with maintenance of HRQoL (measured by the Functional Assessment of Cancer T
SUBMITTER: Brummendorf TH
PROVIDER: S-EPMC7237399 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA